Genaera Begins Phase 1b Trial Of Trodusquemine (MSI-1436) In Overweight And Obese Type 2 Diabetics

Genaera Corporation (Nasdaq: GENR) announced that dosing of subjects has begun in study MSI-1436C-102 (Study 102), the multiple ascending dose Phase 1b study of trodusquemine (MSI-1436) in overweight and obese type 2 diabetics. MSI-1436 is a novel therapeutic for the treatment of type 2 diabetes and obesity which works centrally and peripherally to regulate insulin and leptin pathways through the highly selective inhibition of its novel target enzyme, PTP-1B.

More: continued here

Filed under: Clinical Trials on December 4th, 2008